Antimicrobials
Piperacillin/Tazobactam

Piperacillin/Tazobactam

Medium
N/A
$ (<$25/day)

Dosing

General Information

  • Renal function

  • CBC with differential

  • Bleeding

  • Seizures

  • Encephalopathy

  • Allergic reactions (immediate or delayed)

  • Bone marrow suppression

  • Neurotoxicity (encephalopathy, seizures)

  • Nephrotoxicity

  • Abnormal liver enzymes

  • Diarrhea

  • Headache

Pathogens continue to acquire increased resistance, including resistance to Zosyn. Recent research has shown better outcomes in critically ill patients when Zosyn is used in a modified (extended-infusion) dosing fashion. Additionally, pharmacodynamic/kinetic research has shown improved drug concentration: pathogen MIC ratios with this extended-infusion regimen.

  • Distribution: 0.243L/kg
  • Protein Binding: 
    • Piperacillin: 26-33%
    • Tazobactam: 32%
  • Half-Life: 0.7-1.2 hours
  • Excretion: Clearance of both piperacillin and tazobactam are directly proportional to renal function
    • Piperacillin: 
      • Urine (68% as unchanged drug)
      • Feces (10% to 20%)
    • Tazobactam: Urine (80% as unchanged drug; remainder as inactive metabolite)